Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or …

Glucagon-like peptide-1 receptor agonists (GLP-1s) represent a class of therapeutics with the potential to advance public health and drive societal value. Initially developed for managing …

Global number of patients on GLP -1s across diabetes and obesity Novo Nordisk GLP 1 patient reach Novo Nordisk has almost tripled its global GLP-1 patient reach in 3 years

With mounting evidence of the broad systemic impact and societal value of our GLP-1-based treatments, we have developed innovative commercial strategies to safeguard patient access …

Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or …

When released, GLP-1 stimulates insulin production in the pancreas, which again lowers the amount of glucose in the blood. This is the world’s first oral treatment for type 2 diabetes with a …

Novo Nordisk® Strategic aspirations 2025 Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth 3 Research & early development …

• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 54.8% value market share • Estimated global GLP-1 share of total diabetes

Injection pens and injection needles from Novo Nordisk for diabetes, obesity and growth hormone deficiency. See the types of insulin pens available here and learn how to use our insulin pens.

At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions. Our scientists are currently working on …